What’s New?
Acne patients are benefitting from a robust pipeline with treatments that hold promise for increased efficacy and safety. First-in-class additions to the FDA-approved armamentarium, such as the novel antiandrogen clascoterone (Winlevi; Sun Pharma), give dermatologists and pediatricians new tools to combat this skin condition. Speakers offer insights on matching medications to individual patient needs and controlling costs.
Newsletter
Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.
Andrew Alexis, MD, MPH, highlights positive lebrikizumab-lbkz data for atopic dermatitis
June 25th 2025Lebrikizumab demonstrated efficacy and safety in patients with skin of color and moderate-to-severe atopic dermatitis in the ADmirable trial. Trial investigator Andrew Alexis, MD, MPH, reacts.
